At the news
? NEUTRALIMPACT 4/10 8-K filed May 6, 2026 at 08:00 ET
Novavax reported Q1 2026 total revenue of $140M, down 79% YoY from $667M, which included $603M in non-cash APA close-out sales in Q1 2025. Net loss was $9M vs net income of $519M in the prior year. The company reiterated its FY2026 adjusted total revenue framework of $230M-$270M and expense guidance, with no change to outlook. The headline revenue decline is entirely driven by the prior-year APA close-out, not underlying business deterioration.
- Q1 2026 total revenue $140M, down 79% YoY from $667M (Q1 2025 included $603M non-cash APA close-out)
- Q1 2026 net loss $9M vs net income $519M in Q1 2025
- GAAP diluted EPS $(0.06) vs $2.93 in Q1 2025
- Licensing, royalties and other revenue $97M, up 116% YoY, including $30M Pfizer upfront
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access